Nordea Investment Management AB Lowers Stock Position in Solventum Corporation $SOLV

Key Points

• Nordea Investment Management AB cut its stake in Solventum by 98.1% in Q4, selling 744,185 shares and leaving 14,662 shares valued at about $1.17M per its SEC filing.
• Director Amy McBride Wendell bought 1,475 shares at about $68.03, a 41.39% increase that leaves her with 5,039 shares worth roughly $342,803.
• Solventum beat Q4 estimates with EPS of $1.57 (vs. $1.50) and $2.0B revenue, provided FY 2026 guidance of 6.40–6.60 EPS, and carries an analyst consensus of "Hold" with an average price target of $90.64.

Nordea Investment Management AB cut its holdings in shares of Solventum Corporation (NYSE:SOLV - Free Report) by 98.1% during the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 14,662 shares of the company's stock after selling 744,185 shares during the period. Nordea Investment Management AB's holdings in Solventum were worth $1,169,000 as of its most recent SEC filing.

Several other institutional investors also recently bought and sold shares of SOLV. LSV Asset Management lifted its position in shares of Solventum by 364.5% during the third quarter. LSV Asset Management now owns 35,122 shares of the company's stock valued at $2,564,000 after buying an additional 27,561 shares during the last quarter. Davis Selected Advisers grew its position in shares of Solventum by 0.5% in the 3rd quarter. Davis Selected Advisers now owns 5,517,611 shares of the company's stock worth $402,786,000 after buying an additional 24,950 shares during the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. raised its stake in shares of Solventum by 15.3% during the 3rd quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 307,789 shares of the company's stock worth $22,469,000 after acquiring an additional 40,812 shares in the last quarter. Candriam S.C.A. raised its stake in shares of Solventum by 48.6% during the 3rd quarter. Candriam S.C.A. now owns 80,975 shares of the company's stock worth $5,911,000 after acquiring an additional 26,481 shares in the last quarter. Finally, Pzena Investment Management LLC purchased a new stake in Solventum during the third quarter valued at approximately $31,701,000.

Insider Activity

In other news, Director Amy Mcbride Wendell bought 1,475 shares of the firm's stock in a transaction that occurred on Tuesday, March 10th. The stock was purchased at an average price of $68.03 per share, with a total value of $100,344.25. Following the completion of the acquisition, the director directly owned 5,039 shares of the company's stock, valued at $342,803.17. This trade represents a 41.39% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. 0.05% of the stock is currently owned by insiders.

Solventum Price Performance

NYSE SOLV opened at $62.80 on Friday. The company has a market cap of $10.89 billion, a price-to-earnings ratio of 7.08, a PEG ratio of 1.03 and a beta of 0.40. The company has a debt-to-equity ratio of 1.00, a current ratio of 1.23 and a quick ratio of 0.89. The stock's fifty day moving average price is $73.04 and its 200 day moving average price is $75.50. Solventum Corporation has a 1 year low of $60.70 and a 1 year high of $88.20.

Solventum (NYSE:SOLV - Get Free Report) last posted its quarterly earnings results on Thursday, February 26th. The company reported $1.57 earnings per share for the quarter, beating the consensus estimate of $1.50 by $0.07. The business had revenue of $2 billion for the quarter, compared to the consensus estimate of $1.96 billion. Solventum had a return on equity of 25.26% and a net margin of 18.69%.The company's quarterly revenue was down 3.7% compared to the same quarter last year. During the same quarter in the previous year, the business earned $1.41 EPS. Solventum has set its FY 2026 guidance at 6.400-6.600 EPS. As a group, equities research analysts forecast that Solventum Corporation will post 6.58 earnings per share for the current year.

Analyst Ratings Changes

Several equities analysts have issued reports on the stock. Weiss Ratings reaffirmed a "hold (c)" rating on shares of Solventum in a report on Tuesday, January 27th. Piper Sandler reiterated an "overweight" rating on shares of Solventum in a report on Wednesday, December 17th. BTIG Research reissued a "buy" rating and issued a $100.00 price objective on shares of Solventum in a research report on Friday, February 27th. Mizuho set a $100.00 target price on Solventum and gave the stock an "outperform" rating in a research note on Tuesday, January 20th. Finally, KeyCorp increased their price target on Solventum from $97.00 to $99.00 and gave the company an "overweight" rating in a research note on Friday, February 27th. Seven research analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company presently has an average rating of "Hold" and an average price target of $90.64.

Solventum Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration. The Medsurg segment is a provider of solutions including advanced wound care, I.V. site management, sterilization assurance, temperature management, surgical supplies, stethoscopes, and medical electrodes.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.